Quantitative assessment of lingual strength in late-onset Pompe disease

Muscle and Nerve

Volumn 51, Issue 5, 2015, Pages 731-735

  Jones, Harrison N ^a   Crisp, Kelly D ^b   Asrani, Priyanka ^c   Sloane, Richard ^d   Kishnani, Priya S ^c  

^a Div of Speech Pathol and Audiology   (United States)

^b DUKE UNIVERSITY HOSPITAL   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adult glycogen storage disease type II; Glycogen storage disease type II; Muscle weakness; Pompe disease; Pressure: quantitative muscle testing; Tongue; Transducer

Indexed keywords

ADULT; AGED; AMBULATORY CARE; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DYSARTHRIA; ENZYME REPLACEMENT; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LATE ONSET POMPE DISEASE; LINGUAL STRENGTH; MALE; MIDDLE AGED; MORBIDITY; MUSCLE STRENGTH; MUSCLE WEAKNESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SPEECH ANALYSIS; SPEECH AND LANGUAGE ASSESSMENT; SPEECH ARTICULATION; TONGUE WEAKNESS; TREATMENT DURATION; YOUNG ADULT; GLYCOGEN STORAGE DISEASE TYPE II; INCIDENCE; ONSET AGE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TONGUE;

ADULT; AGE OF ONSET; AGED; CHILD; DYSARTHRIA; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE WEAKNESS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TONGUE;

EID: 84928206371     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24523     Document Type: Article

References (21)

1. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8:267-288.
2. Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 2010;257:91-97.
3. Van der Ploeg A, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin R, et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab 2012;107:456-461.
4. Muller CS, Jones HN, O'Grady G, Suarez AH, Heller JH, Kishnani PS. Language and speech function in children with infantile Pompe disease. J Pediatr Neurol 2009;7:147-156.
5. Hudgson P, Gardner-Medwin D, Worsfold M, Pennington RJ, Walton JN. Adult myopathy from glycogen storage disease due to acid maltase deficiency. Brain 1968;91:435-462.
6. van der Walt JD, Swash M, Leake J, Cox EL. The pattern of involvement of adult-onset acid maltase deficiency at autopsy. Muscle Nerve 1987;10:272-281.
7. Felice KJ, Alessi AG, Grunnet ML. Clinical variability in adult-onset acid maltase deficiency: report of affected sibs and review of the literature. Medicine (Baltimore) 1995;74:131-135.
8. Margolis MM HP, Goldberg R, Eftychiadia A, Levine S. Obstructive sleep apnea in acid maltase deficiency. Chest 1994;105:947-949.
9. Carlier RY, Laforet P, Wary C, Mompoint D, Laloui K, Pellegrini N, et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: Involvement patterns. Neuromuscul Disord 2011;21:791-799.
10. Dubrovsky A, Corderi J, Lin M, Kishnani PS, Jones HN. Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation. Muscle Nerve 2011;44:897-901.
11. Hogrel JY, Payan C, Ollivier G, Tanant V, Attarian S, Couillandre A, et al. Development of a French isometric strength normative database for adults using quantitative muscle testing. Arch Physiol Med Rehabil 2007;88:1289-1297.
12. Tiffreau V, Ledoux I, Eymard B, Thevenon A, Hogrel JY. Isokinetic muscle testing for weak patients suffering from neuromuscular disorders: a reliability study. Neuromuscul Disord 2007;17:524-531.
13. Adams V, Mathisen B, Baines S, Lazarus C, Callister R. A systematic review and meta-analysis of measurements of tongue and hand strength and endurance using the Iowa Oral Performance Instrument (IOPI). Dysphagia 2013;28:350-369.
14. Palmer PM, Neel AT, Sprouls G, Morrison L. Swallow characteristics in patients with oculopharyngeal muscular dystrophy. J Speech Lang Hear Res 2010;53:1567-1578.
15. Easterling C, Antinoja J, Cashin S, Barkhaus PE. Changes in tongue pressure, pulmonary function, and salivary flow in patients with amyotrophic lateral sclerosis. Dysphagia 2013;28:217-225.
16. IOPI Medical. IOPI User Manual 2.2. Redmond, WA: IOPI Medical.
17. Potter NL, Short R. Maximal tongue strength in typically developing children and adolescents. Dysphagia 2009;24:391-397.
18. Duffy J. Motor speech disorders: substrates, differential diagnosis, and management. St Louis, MO: Elsevier Mosby; 2013.
19. Yorkston KM BD, Strand EA, Hakel M. Management of motor speech disorders in children and adults. Austin, Texas: Pro-ed; 2010.
20. World Health Organization. ICF: International Classification of Functioning, Disability, and Health. Geneva: WHO; 2001.
21. Zhong X NM, Kannengiesser SA, Dale BM, Kiefer B, Bashir MR. Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging. Magn Reson Med 2014;72:1353-1365.